B
boley
⚪
В Медлайне по дескриптору "orthokin" найдено три публикации. Все родом из Германии. Вторая публикация - это исследование, котрое мы уже анализировали (in vitro).
Первая публикация (старый, правда, обзор) : фрагмент привожу.
Orthopade. 2001 Nov;30(11):856-65. Related Articles, Links
[Drug therapy of arthrosis]
[Article in German]
Steinmeyer J.
Orthopadische Klinik, Universitatsklinikum Giessen. juergen.steinmeyer@ortho.med.uni-giessen.de
However, no clinical studies exist which can positively confirm prevention of morphologically recognizable cartilage defects in man, or a slowing down or reversal of any progressively developing joint cartilage destruction by any individual medication. Neither the benefits, risks, pharmaceutical quality, nor composition of Orthokin are known, and for this reason its use can not be recommended. Pharmacotherapy should only be considered as one of the three pillars of a long-term,stage-adjusted, and individually customized therapy, the other two of which are represented by nonpharmacological measures and surgical treatment.
А вот и последний обзор от 2004 года. Тоже из Германии родом.
Versicherungsmedizin. 2004 Mar 1;56(1):30-2. Related Articles, Links
[Orthokin as new therapeutic option for orthopedic diseases]
[Article in German]
Heyll U.
Aus der Abteilung Medizinische Beratung der Deutschen Krankenversicherung, Koln.
The synthesis and introduction of interleukin-1 receptor antagonists established a promising strategy in the treatment of inflammatory diseases. This kind of therapy is claimed now to be available for osteoarthritis and other orthopedic disorders also. In the case of "orthokin", the interleukin-1 receptor antagonist is produced by stimulation of own blood-cells. It is not possible, to evaluate the practicability of this therapeutic approach because there are no published experimental data. We also found no results of clinical studies, which would allow an estimation of the effectiveness and the risks of this method. Therefore treatment with "orthokin" cannot be recommended at present.
Первая публикация (старый, правда, обзор) : фрагмент привожу.
Orthopade. 2001 Nov;30(11):856-65. Related Articles, Links
[Drug therapy of arthrosis]
[Article in German]
Steinmeyer J.
Orthopadische Klinik, Universitatsklinikum Giessen. juergen.steinmeyer@ortho.med.uni-giessen.de
However, no clinical studies exist which can positively confirm prevention of morphologically recognizable cartilage defects in man, or a slowing down or reversal of any progressively developing joint cartilage destruction by any individual medication. Neither the benefits, risks, pharmaceutical quality, nor composition of Orthokin are known, and for this reason its use can not be recommended. Pharmacotherapy should only be considered as one of the three pillars of a long-term,stage-adjusted, and individually customized therapy, the other two of which are represented by nonpharmacological measures and surgical treatment.
А вот и последний обзор от 2004 года. Тоже из Германии родом.
Versicherungsmedizin. 2004 Mar 1;56(1):30-2. Related Articles, Links
[Orthokin as new therapeutic option for orthopedic diseases]
[Article in German]
Heyll U.
Aus der Abteilung Medizinische Beratung der Deutschen Krankenversicherung, Koln.
The synthesis and introduction of interleukin-1 receptor antagonists established a promising strategy in the treatment of inflammatory diseases. This kind of therapy is claimed now to be available for osteoarthritis and other orthopedic disorders also. In the case of "orthokin", the interleukin-1 receptor antagonist is produced by stimulation of own blood-cells. It is not possible, to evaluate the practicability of this therapeutic approach because there are no published experimental data. We also found no results of clinical studies, which would allow an estimation of the effectiveness and the risks of this method. Therefore treatment with "orthokin" cannot be recommended at present.
Многие частные мед. страховые компании признали и оплачивают лечение. 
